Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01029925 | Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL) | terminated | Phase 2 | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00299390 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | terminated | Phase 2 | 10 | BayerINDUSTRY | 0 | Dec 31, 2015 | clinicaltrials |
| NCT00298298 |
| DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer |
| terminated |
| Phase 1 / Phase 2 |
| 6 |
| AVAX TechnologiesINDUSTRY |
| 1 |
| Dec 3, 2015 |
| clinicaltrials |
| NCT00988169 | Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | terminated | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01189435 | Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01193868 | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy | terminated | Phase 2 | 13 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01577212 | Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy(IDEAL-VMAT) | terminated | Phase 2 | 6 | Radboud University Medical CenterOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00530634 | Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer | terminated | Phase 2 | 3 | City of Hope Medical CenterOTHER | 0 | Oct 29, 2015 | clinicaltrials |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | terminated | Phase 2 | 255 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT00923949 | Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00749567 | Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer | terminated | Phase 2 | 13 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT02179567 | Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC | terminated | Phase 2 | 26 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01057212 | Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT00983047 | Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer | terminated | Phase 2 | 30 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00391586 | Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung | terminated | Phase 2 | 45 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 17, 2015 | clinicaltrials |
| NCT00290550 | A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) | terminated | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2015 | clinicaltrials |
| NCT01222572 | Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01421316 | Hair-sparing Whole Brain Radiotherapy | terminated | Phase 2 | 29 | University Hospital, GhentOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00431613 | Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 38 | Hellenic Oncology Research GroupOTHER | 1 | May 29, 2015 | clinicaltrials |
| NCT01038752 | Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer | terminated | Phase 2 | 14 | Optimum Therapeutics, LLCINDUSTRY | 1 | May 21, 2015 | clinicaltrials |
| NCT00238615 | Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC | terminated | Phase 2 | 13 | Stanford UniversityOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00974662 | Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer | terminated | Phase 2 | 3 | Steba Biotech S.A.OTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00940875 | A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 54 | Hoffmann-La RocheINDUSTRY | 1 | Apr 2, 2015 | clinicaltrials |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | terminated | Phase 1 / Phase 2 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00564876 | Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer(TOP0706) | terminated | Phase 2 | 2 | Duke UniversityOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00661011 | Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy | terminated | Phase 2 | 75 | European Lung Cancer Working PartyOTHER | 3 | Feb 12, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00559897 | Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 6 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT00818675 | A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) | terminated | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 21, 2015 | clinicaltrials |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | terminated | Phase 2 / Phase 3 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00452075 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy | terminated | Phase 2 | 24 | Rigshospitalet, DenmarkOTHER | 1 | Dec 11, 2014 | clinicaltrials |
| NCT01664663 | Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy(PLANET) | terminated | Phase 2 | 37 | Ass. Prof. Jan NymanNETWORK | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01038037 | First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer(Lung-TRIO) | terminated | Phase 2 | 23 | Vejle HospitalOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00726986 | Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 18 | Afshin Dowlati, MDOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01049776 | GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line | terminated | Phase 2 | 32 | Illinois CancerCare, P.C.OTHER | 1 | Sep 19, 2014 | clinicaltrials |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | terminated | Phase 1 / Phase 2 | 43 | Duke UniversityOTHER | 0 | Sep 15, 2014 | clinicaltrials |
| NCT00509366 | Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer(TOP0602) | terminated | Phase 2 | 101 | Duke UniversityOTHER | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00373204 | Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) | terminated | Phase 2 | 50 | Pharmacyclics LLC.INDUSTRY | 4 | Jul 24, 2014 | clinicaltrials |
| NCT00545948 | Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer(TOP0703) | terminated | Phase 2 | 31 | Duke UniversityOTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT01491633 | Dasatinib in Advanced Squamous Cell Lung Cancer | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 15, 2014 | clinicaltrials |
| NCT02157116 | Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 13 | Duke UniversityOTHER | 1 | Jul 4, 2014 | clinicaltrials |
| NCT00145418 | Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 15 | Oncology Specialists, S.C.OTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00528775 | Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages | terminated | Phase 2 | 6 | Roswell Park Cancer InstituteOTHER | 1 | Jun 10, 2014 | clinicaltrials |
| NCT00544648 | Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC | terminated | Phase 1 / Phase 2 | 13 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00976677 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00084487 | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2016source: clinicaltrials